Synchrony™ Bioabsorbable Polymer Coating is applied only to the abluminal side of the stent to stimulate healthy endothelialization.
Patient experience: Vincent’s Father and two Uncles all passed away from heart disease at an early age. But he was determined to rewrite his “legacy,” as he calls it.
Discover why Dr. Antonio Colombo from San Rafaelle in Milan, Italy uses SYNERGY in his daily practice.
SYNERGY Stent engineers explain the science behind the design goal to provide optimal healing and to improve patient outcomes, among all types of complexities.
This OCT study of LAD stents 2-months post-implant show consistent, full strut coverage of the SYNERGY Stent compared to a bioabsorbable vascular scaffold (BVS).*
Drug-eluting stent technology has shown encouraging efficacy compared to bare metal stents, significantly reducing restenosis and revascularization procedures. Still, there remains a concern for being able to treat ever-increasing complex patients, ensuring proper healing, and managing dual antiplatelet therapy (DAPT).
What if there was a technology that offered the benefits of being able to improve the ability to acutely treat complex patients, improve the healing properties, and potentially free selected patients from long-term DAPT?**
Designed to help patients, including those with complex cases, heal from day one and beyond.
The SYNERGY Stent design goals are to address needs surrounding complex PCI. As a result, Boston Scientific established a robust clinical trial program and is supporting investigator-sponsored research7 (ISR) that will study the SYNERGY Stent in many different patient populations that interventional cardiologists see in their everyday practice.
Boston Scientific has received approval to update the indications section of the Directions for Use to include the treatment of patients presenting with coronary artery ostial lesions, unprotected left main coronary artery lesions, coronary artery total occlusion lesions, and in-stent restenosis in coronary artery lesions.
Added recommendations include: For treatment of occluded vessels, contrast visualization of the distal vessel to confirm position of guidewire within the lumen is recommended. For in stent restenosis, where details of the original stent are known, the expanded inner diameter of the new stent should not exceed the dilation limits of the original stent. Where details of the original stent are not known, the expanded inner diameter of the new stent should not exceed the reference vessel diameter.
^ The updated Directions for Use will also include an update on the current “Pre-and Post-Procedure Antiplatelet Regimen”:
In selected higher risk patients where the physician determines that the risks outweigh the benefits of continued DAPT, it may be reasonable to interrupt or discontinue therapy after 1 month based on low stent thrombosis rates and no observed increased risk for stent thrombosis as shown in the current literature. Patients who require premature discontinuation of antiplatelet therapy should be monitored closely and have their antiplatelet therapy restarted as soon as possible per the discretion of their treating physicians